TrialJournal of the neurological sciences2011

Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

George P Christophi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.